AVDL — Avadel Pharmaceuticals PLC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals PLC (AVDL) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Gregory J. Divis Jr., based in 10 Earlsfort Terrace, Dublin, Ireland, D02 T380, with about 188 employees. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Latest reported AVDL revenue for 2025-09-30 was $77.5M. Net income was $20.0K. Revenue was up 13.7% from 2025-06-30 to 2025-09-30. AVDL currently screens at market cap $968.5M.
Use this AVDL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVDL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVDL SEC filings page. Lician reads the product cache first so this HTML stays unique to Avadel Pharmaceuticals PLC even when a live quote feed is slow.
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
AVDL Key Statistics
Market Cap
$968.53M
EPS
-$0.51
Revenue
$169.12M
Net Income
-$48.83M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+504.8%
Profit Margin
-28.9%
Employees
188
AVDL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $169.12M | $27.96M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$48.83M | -$160.28M | -$137.46M | -$77.33M |
| EPS (Diluted) | -$0.51 | -$2.00 | -$2.29 | -$1.32 |
Total Assets
$164.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$51.37M
Operating Cash Flow
-$46.91M
Free Cash Flow
$0.00
Avadel Pharmaceuticals PLC Company Information
- CEO & Director
- Gregory J. Divis Jr.
- Headquarters
- 10 Earlsfort Terrace, Dublin, Ireland, D02 T380
- Website
- www.avadel.com
- Phone
- 353 1 901 5201
- IPO / Founded
- 1996-06-07
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic